Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431275 · ClinicalTrials.gov registry record · Phase 1
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00431275 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 85 participants.
The verdict
NCT00431275, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.
Interventions
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00431275
The ClinicalTrials.gov registry entry for NCT00431275 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-675,206 is the first listed.
NCT00431275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00431275 about?
NCT00431275 is a clinical study titled "Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody". This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two fo...
What is the current status of trial NCT00431275?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2006-06. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00431275?
The interventions under investigation include: CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00431275?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.